Ken Griffin Shattuck Labs, Inc. Transaction History
Citadel Advisors LLC
- $483 Billion
- Q2 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Shattuck Labs, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 3,100 shares of STTK stock, worth $11,811. This represents 0.0% of its overall portfolio holdings.
Number of Shares
3,100
Previous 15,900
80.5%
Holding current value
$11,811
Previous $142,000
92.25%
% of portfolio
0.0%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding STTK
# of Institutions
76Shares Held
26.8MCall Options Held
3.1KPut Options Held
23.9K-
Redmile Group, LLC San Francisco, CA5.62MShares$21.4 Million1.41% of portfolio
-
Prosight Management, LP Dallas, TX4.67MShares$17.8 Million5.63% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA2.75MShares$10.5 Million0.02% of portfolio
-
Black Rock Inc. New York, NY2.47MShares$9.43 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.3MShares$8.77 Million0.0% of portfolio
About Shattuck Labs, Inc.
- Ticker STTK
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 42,382,000
- Market Cap $161M
- Description
- Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also develops SL-279252 that is ...